Journal: Advanced Science

Article Title: Human Platelet Lysates‐Based Hydrogels: A Novel Personalized 3D Platform for Spheroid Invasion Assessment

doi: 10.1002/advs.201902398

Figure Lengend Snippet: Protein and growth factor release from PLMA hydrogels. A) Total protein quantification and B,C) ELISA quantification of TGF‐β1 and VEGF‐A release from PLMA hydrogels at 10, 15, and 20% (w/v). Data are presented as mean ± SD ( n ≥ 3).

Article Snippet: ELISA assays were performed to quantify the release of vascular endothelial growth factor (VEGF Human ELISA Kit, Invitrogen, ThermoFisher Scientific, USA), transforming growth factor β1 (TGF‐β1 Human ELISA Kit, Invitrogen, ThermoFisher Scientific, USA), and epidermal growth factor (Human EGF Quantikine ELISA Kit, R&D systems, Minneapolis, USA).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: NPJ Regenerative Medicine

Article Title: Scaffolds with spatiotemporally controlled growth factor delivery and cyclodextrin-enabled antagonism of growth factor receptor sequestration promote cutaneous wound healing

doi: 10.1038/s41536-025-00431-0

Figure Lengend Snippet: a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d ELISA demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).

Article Snippet: For determination of growth factor release from the hydrogels, gelatin hydrogels were loaded onto 0.4 μm PET membranes within a 24 well plate, submerged in PBS, and growth factor release quantified at 0, 12, 24, 48, 96 and 120 h using respective Quantikine ELISA kits (R&D Systems, DEG00 for EGF, DBB00 for PDGF-BB, and DVE00 for VEGF).

Techniques: Comparison, Immunohistochemistry, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in medicine

Article Title: Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2.

doi: 10.3389/fmed.2022.1012827

Figure Lengend Snippet: FIGURE 1 Biomarker plasma levels in sarcoidosis and healthy controls. Plasma levels medians are plotted. Compared to healthy controls, each biomarker exhibited higher values in plasma of sarcoidosis patients. Except for IL-8 all of plasma biomarkers were significantly higher in sarcoidosis. eNAMPT (2.1 vs. 1.2 ng/ml), IL-6 (1.2 vs. 0.6 pg/ml), ANG-2 (2.7 vs. 1.0 pg/ml), HBEGF (5.9 vs. 1 pg/ml), and IL-1 RA (227 vs. 82.3 pg/ml). Mann–Whitney test was calculated for each comparison; ****p-values < 0.0001 and *p < 0.05.

Article Snippet: 150 μl of plasma was used to quantify HBEGF levels using Quantikine R© ELISA Human HBEGF immunoassay (R&D Systems R©), quantitative sandwich enzyme immunoassay technique.

Techniques: Biomarker Discovery, Clinical Proteomics, MANN-WHITNEY, Comparison

Journal: Frontiers in medicine

Article Title: Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2.

doi: 10.3389/fmed.2022.1012827

Figure Lengend Snippet: FIGURE 2 Circulating biomarkers in complicated sarcoidosis and pulmonary fibrosis. (A) The plasma levels of HBEGF were significantly elevated (**p < 0.003) in a group of 62 complicated sarcoidosis (parenchymal lung disease by CT scan, radiographic Scadding stages III and IV; Forced vital capacity (FVC) < 50%; cardiac or neurological involvement in addition to lung involvement) compared to non-complicated sarcoidosis. (B) ANG-2 plasma levels were significantly (p < 0.017) elevated in 19 subjects with sarcoidosis and pulmonary fibrosis (confirmed fibrotic changes on high-resolution chest CT scan or radiographic stage IV) compared to those with non-fibrosis.

Article Snippet: 150 μl of plasma was used to quantify HBEGF levels using Quantikine R© ELISA Human HBEGF immunoassay (R&D Systems R©), quantitative sandwich enzyme immunoassay technique.

Techniques: Clinical Proteomics, Computed Tomography

Journal: Frontiers in medicine

Article Title: Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2.

doi: 10.3389/fmed.2022.1012827

Figure Lengend Snippet: FIGURE 3 The receiver-operator characteristics curves (ROC) assessing the diagnostic accuracy power. (A–E) Sarcoidosis vs. controls. eNAMPT (A), IL-6 (B), IL-1RA (C), ANG-2 (D), and HBEGF (E). IL-1RA showed the highest discriminatory accuracy between sarcoidosis and healthy controls (AUC of 0.93, 95% CI of 0.90–0.95), followed by ANG-2 (AUC 0.85, 95% CI of 0.79–0.90). (F,G) Progressive sarcoidosis. ANG-2 diagnostic accuracy performed well to distinguish sarcoidosis pulmonary fibrosis vs. sarcoidosis without pulmonary involvement (Stages I and II) (F) and HBEGF showed a good discriminatory power to differentiate complicated sarcoidosis.

Article Snippet: 150 μl of plasma was used to quantify HBEGF levels using Quantikine R© ELISA Human HBEGF immunoassay (R&D Systems R©), quantitative sandwich enzyme immunoassay technique.

Techniques: Diagnostic Assay

Journal: Frontiers in medicine

Article Title: Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2.

doi: 10.3389/fmed.2022.1012827

Figure Lengend Snippet: FIGURE 4 (A–F) Representative immunohistochemical staining of lymph nodes (A,C,E) and lung tissues (B,D,F) from sarcoidosis compared healthy controls 40 × magnification. ANG-2 (A,B,G), HBEGF (C,D,H), NAMPT (E,F,I). (G–I) Bar graphs (G) illustrate quantification of mean proportions of ANG-2, HBEGF, and NAMPT *p < 0.05. Sarcoidosis in dark gray and normal tissue in light gray. ANG-2 expression in lung tissue and lymph node in sarcoidosis was 32.2 and 33.7%, respectively, in contrast to the expression observed in normal lung and lymph nodes was 9.8 and 11.3%, respectively (p = 1.2 e-04). HBEGF expression in sarcoidosis lymph nodes was 44.8% vs. 4.8% in normal lymph nodes (p = 3.8 e-05); in normal lungs was 18.3% contrasting with 60.4% in lung of sarcoidosis (p = 4.0 e-05). NAMPT mean proportions in lymph nodes were 12.7% in normal tissue and 52% in sarcoidosis (p = 4.9 e-04); while in normal lungs was 23.3% vs. 53% in sarcoidosis (p = 9.2 e-040. in lymph nodes).

Article Snippet: 150 μl of plasma was used to quantify HBEGF levels using Quantikine R© ELISA Human HBEGF immunoassay (R&D Systems R©), quantitative sandwich enzyme immunoassay technique.

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Frontiers in medicine

Article Title: Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2.

doi: 10.3389/fmed.2022.1012827

Figure Lengend Snippet: FIGURE 5 Enrichment analysis of DEGs in lung tissues from subjects with sarcoidosis compared to healthy lung. Functional protein network interaction showing eNAMPT and HBEGF relationship with regulators of lung fibrosis (MMP9), inflammation, and lung remodeling and NOTCH4, a T-cell activity and angiogenesis regulator. Each node represents a coded protein. The edges represent protein–protein associations (line color indicates type of interaction: green—gene neighborhood, red—gene fusion, blue—co-occurrence, and black—co-expression). Pathway analysis and first shell interactors members included are indicated by the color code. A complete list of dysregulated pathways is presented in Supplementary Table 2.

Article Snippet: 150 μl of plasma was used to quantify HBEGF levels using Quantikine R© ELISA Human HBEGF immunoassay (R&D Systems R©), quantitative sandwich enzyme immunoassay technique.

Techniques: Functional Assay, Activity Assay, Expressing